Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

ABSTRACT:

Importance

Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL).

Objective

To examine the association of TTFields therapy with progression-free survival and HRQoL among patients with glioblastoma.

Design, setting, and participants

This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy. Patients with glioblastoma were randomized 2:1 to combined treatment with TTFields and temozolomide or temozolomide alone. The study was conducted from July 2009 until Nov

SUBMITTER: Taphoorn MJB 

PROVIDER: S-EPMC5885193 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature